Immunoreactive EGF in human benign prostatic hyperplasia: relationships with androgen and estrogen receptors
| Autor: | F. Palleschi, Elisa Petrangeli, F. Sciarra, Carla Lubrano, E. Palma, N. Rombola, F. Di Silverio, Vincenzo Toscano, E. Spera |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Male
medicine.medical_specialty medicine.drug_class Endocrinology Diabetes and Metabolism Clinical Biochemistry Prostatic Hyperplasia Radioimmunoassay Estrogen receptor urologic and male genital diseases Biochemistry Cytosol Endocrinology Epidermal growth factor Internal medicine medicine Humans Receptor Molecular Biology Aged Cell Nucleus Epidermal Growth Factor Chemistry Prostate DNA Cell Biology Middle Aged Hyperplasia Androgen medicine.disease Androgen receptor Receptors Estrogen Receptors Androgen Estrogen Sex steroid Molecular Medicine hormones hormone substitutes and hormone antagonists |
| Zdroj: | The Journal of Steroid Biochemistry and Molecular Biology. 41:683-687 |
| ISSN: | 0960-0760 |
| DOI: | 10.1016/0960-0760(92)90404-7 |
| Popis: | Benign prostatic hyperplasia (BPH) is a sex steroid dependent disease. Estrogens and androgens can modulate in different mammalian tissues epidermal growth factor (EGF) production and/or secretion. In order to clarify the relationships between estrogen and androgen receptor concentrations and those of immunoreactive EGF (irEGF), we have evaluated these parameters in 14 human BPH samples, by means of a dextran-coated charcoal method and radioimmunoassay, respectively. Cytosolic steroid receptors did not seem to correlate with irEGF. A linear significative relationship was evident between nuclear androgen receptor (ARn) levels and endogenous irEGF but not between nuclear estrogen receptors and irEGF: in ARn negative BPH samples, irEGF levels were lower than in ARn positive ones. Therefore, it is possible that androgens act at prostatic tissue level, through their own receptors, by modulating EGF production and/or secretion. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|